RBC Capital Maintains Outperform on Cytokinetics, Lowers Price Target to $80

Benzinga · 05/07 17:02
RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and lowers the price target from $82 to $80.